10x Genomics Inc. stocks have been trading up by 13.62 percent amid strong sentiment on its latest product innovation news
What Traders Need To Know
- Q2 2026 revenue came in at $151M, ahead of roughly $146.6M–$146.7M expectations, with about 3% like-for-like growth after stripping out prior patent settlement revenue.
- The company posted a Q2 loss of $0.14 per share versus a projected $0.24 loss and nudged 2026 revenue guidance up to $610M–$630M, slightly above both prior guidance and Street consensus.
- Management flagged strong early Atera demand, 74% gross margin, closure of the Proteintech Genomics deal, and fresh cancer diagnostics collaborations as key growth drivers.
- Stifel doubled its price target from $25 to $50 with a Buy rating, while Citi and Morgan Stanley also raised targets to $50 and $40 but stayed Neutral/Equal Weight.
- A new multi-year collaboration with Lausanne University Hospital will use Flex Apex, Xenium, and Atera in advanced cancer diagnostics research to showcase how single-cell and spatial tools can support clinical decisions.
Weekly Update Aug 03 – Aug 07, 2026: On Sunday, August 09, 2026 10x Genomics Inc. stock [NASDAQ: TXG] is trending up by 13.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
10x Genomics occupies a leading position in single-cell and spatial genomics with 6–14% multi‑year revenue CAGRs and Q2 revenue of $151M, but remains sub‑scale and loss‑making. Gross margin near 70% and 74% in Q2 is best‑in‑class for tools, yet EBIT margin (~‑3%) and ROIC are negative, reflecting heavy R&D and G&A. Balance sheet strength is a clear asset: net cash >$500M, minimal leverage (debt/equity 0.1), current ratio 5.9, and positive free cash flow of ~$15M last quarter.
Technically, TXG has shifted from a consolidation in the mid‑$40s to an emerging uptrend, with a sharp recovery from the 8/6 intraday low near $42.70 to a $51.81 close on 8/7, confirming aggressive dip buying post‑earnings. Volume on the 8/7 breakout was significantly above recent averages, validating $50 as a key pivot. For trading, $50 should be treated as first support and a tactical stop level, with upside momentum targeting the mid‑$50s near term.
More Breaking News
- REGN Stock Climbs As Libtayo Data And Targets Rise
- MPT Stock Slides As Traders Weigh Debt, Dividend Risk
- CDE Stock Pullback Has Active Metals Traders On Watch
- CMCSA Rallies As Earnings Beat Collides With Restructuring Overhang
Fundamentally, TXG is levered to a 12%+ CAGR multiomics market and continues to outgrow most life‑science tools peers, while operating losses remain larger than mature healthcare and tools benchmarks. The Atera launch, CHUV collaboration, and Proteintech Genomics acquisition, combined with a guidance raise to $610–630M, justify recent target hikes (Stifel and Citi to $50). I view risk‑reward as favorable with a 6–12 month target of $60 and near‑term support at $50 and secondary support at $43.
Quick Financial Overview
10x Genomics Inc. is showing that it can still grow in a tougher environment, but the growth is modest and not yet flowing to the bottom line. Q2 2026 revenue was $151M and, on a like-for-like basis, that represents roughly 3% growth over the prior year once one-off patent settlement revenue is removed. Gross margin improved to 74%, which is strong for a life-science tools name, yet the company reported a net loss of $17.9M and an EBITDA loss of $5.5M, reminding traders that TXG is still in build-out mode.
From a balance sheet angle, 10x Genomics Inc. is in solid shape. Cash and equivalents stand near $502.5M, with cash and short-term investments around $552.0M against total liabilities of roughly $204.5M. Leverage is low, with long-term debt near $66.8M and a current ratio around 5.9, suggesting TXG has room to keep funding product development like Atera and the Proteintech Genomics integration without near-term financing stress.
Valuation remains rich, which is important for traders. With trailing revenue of about $642.8M, a price-to-sales ratio of 10.34 and price-to-cash-flow above 60 show the market is still paying up for growth. Profitability ratios are deeply negative, including return on equity and return on assets, so the bull case rests on sustained revenue gains and operating leverage from high gross margin. That is why the guidance bump to $610M–$630M and analyst target hikes matter so much for TXG’s short-term trading profile.
Conclusion
TXG is trading like a classic high-growth tools name: strong gross margin, clean balance sheet, but still losing money and priced for future execution. The weekly tape shows typical post-earnings volatility, with a dip toward the low-$40s followed by a sharp push into the low-$50s, lining up with the earnings beat, guidance raise, and aggressive target hike from Stifel to $50. Intraday, the wide $44–$52 range tells you liquidity is there, but so is fast money, which can cut both ways for short-term trades.
Fundamentally, 10x Genomics Inc. has several wind-at-its-back factors. The global multiomics market is projected to expand from $3.18B in 2026 to $5.70B by 2031, and TXG’s platforms in single-cell and spatial tools leave it well placed to tap that trend. The Atera launch, stronger gross margin, Q2 beats on both revenue and EPS, and the Lausanne cancer collaboration all support the growth story, while the raised 2026 guidance and multiple price-target increases help sentiment even as some brokers remain cautious.
For traders, the risk/reward in TXG hinges on whether that modest 3% like-for-like growth can accelerate enough to justify premium multiples. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.”, and that mindset is especially relevant here as TXG trades around key technical levels and evolving fundamentals. Breaks above recent highs in the low-$50s on strong volume would confirm that institutions are leaning into the Stifel view, while any rejection there could send the stock back to test the mid-$40s where post-earnings buyers first stepped in. As I often tell my students, “In names like 10x Genomics Inc., the edge comes from marrying the story to the levels—trade the reaction to each new data point, not the dream.” This article is for educational and research purposes only. “,”scores”:{“risk-level”:”medium-high”},”trade”:”true
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.